Bone Biologics Corp
NASDAQ:BBLG
Intrinsic Value
Bone Biologics Corp. operates as a medical device company, which engages in the research and development of bone regeneration in spinal fusion. [ Read More ]
The intrinsic value of one BBLG stock under the Base Case scenario is 3.4393 USD. Compared to the current market price of 1.5251 USD, Bone Biologics Corp is Undervalued by 56%.
Valuation Backtest
Bone Biologics Corp
Run backtest to discover the historical profit from buying and selling BBLG stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Bone Biologics Corp
Current Assets | 3.7m |
Cash & Short-Term Investments | 3m |
Other Current Assets | 711.2k |
Current Liabilities | 831.4k |
Accounts Payable | 360.7k |
Accrued Liabilities | 415k |
Other Current Liabilities | 55.8k |
Earnings Waterfall
Bone Biologics Corp
Revenue
|
0
USD
|
Operating Expenses
|
-9.4m
USD
|
Operating Income
|
-9.4m
USD
|
Other Expenses
|
479.6k
USD
|
Net Income
|
-8.9m
USD
|
Free Cash Flow Analysis
Bone Biologics Corp
BBLG Profitability Score
Profitability Due Diligence
Bone Biologics Corp's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Bone Biologics Corp's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
BBLG Solvency Score
Solvency Due Diligence
Bone Biologics Corp's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Bone Biologics Corp's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BBLG Price Targets Summary
Bone Biologics Corp
Ownership
BBLG Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
BBLG Price
Bone Biologics Corp
Average Annual Return | -35.09% |
Standard Deviation of Annual Returns | 83.51% |
Max Drawdown | -100% |
Market Capitalization | 1.3m USD |
Shares Outstanding | 880 000 |
Percentage of Shares Shorted | 1.78% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Bone Biologics Corp. operates as a medical device company, which engages in the research and development of bone regeneration in spinal fusion. The company is headquartered in Burlington, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2015-11-27. The firm is also focused on bone regeneration in spinal fusion using the recombinant human protein, known as NELL-1/DBX. The NELL-1/DBX medical device is a combination product which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The NELL-1/DBX Fusion Device offers a range of procedures including Spine Implants, Non-Union Trauma Cases and Osteoporosis. NELL-1 is a function specific recombinant human protein in laboratory bench models to recapitulate normal human growth and development to provide control over bone and cartilage regeneration. The platform technology is its human protein, known as NELL-1, a skeletal specific growth factor which is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration.
Contact
IPO
Employees
Officers
The intrinsic value of one BBLG stock under the Base Case scenario is 3.4393 USD.
Compared to the current market price of 1.5251 USD, Bone Biologics Corp is Undervalued by 56%.